Abstract:Abstract Background Alzheimer’s disease (AD) mutations in amyloid precursor protein ( APP ) and presenilins ( PSENs ) could potentially lead to the production of longer amyloidogenic Aβ peptides. Amongst these, Aβ 1–43 is more prone to aggregation and has higher toxic properties than the long-known Aβ 1–42 . However, a direct effect on Aβ 1–43 in biomaterials of individuals carrying genetic mutations in the known AD genes is yet to be determined. Methods N = 1431 AD patients ( n = 280 early-onset (EO) and n = 1151 late-onset (LO) AD) and 809 control individuals were genetically screened for APP and PSENs . For the first time, Aβ 1–43 levels were analysed in cerebrospinal fluid (CSF) of 38 individuals carrying pathogenic or unclear rare mutations or the common PSEN1 p.E318G variant and compared with Aβ 1–42 and Aβ 1–40 CSF levels. The soluble sAPPα and sAPPβ species were also measured for the first time in mutation carriers. Results A known pathogenic mutation was identified in 5.7% of EOAD patients (4.6% PSEN1 , 1.07% APP ) and in 0.3% of LOAD patients. Furthermore, 12 known variants with unclear pathogenicity and 11 novel were identified. Pathogenic and unclear mutation carriers showed a significant reduction in CSF Aβ 1–43 levels compared to controls ( p = 0.037; < 0.001). CSF Aβ 1–43 levels positively correlated with CSF Aβ 1–42 in both pathogenic and unclear carriers and controls (all p < 0.001). The p.E318G carriers showed reduced Aβ 1–43 levels ( p < 0.001), though genetic association with AD was not detected. sAPPα and sAPPβ CSF levels were significantly reduced in the group of unclear ( p = 0.006; 0.005) and p.E318G carriers ( p = 0.004; 0.039), suggesting their possible involvement in AD. Finally, using Aβ 1–43 and Aβ 1–42 levels, we could re-classify as “likely pathogenic” 3 of the unclear mutations. Conclusion This is the first time that Aβ 1–43 levels were analysed in CSF of AD patients with genetic mutations in the AD causal genes. The observed reduction of Aβ 1–43 in APP and PSENs carriers highlights the pathogenic role of longer Aβ peptides in AD pathogenesis. Alterations in Aβ 1–43 could prove useful in understanding the pathogenicity of unclear APP and PSENs variants, a critical step towards a more efficient genetic counselling.

Screening and Functional Validations of APP, PSEN1 and PSEN2 Mutations from PUMCH Dementia Cohort

Clinical And Neuroimaging Characterization Of Chinese Dementia Patients With Psen1 And Psen2 Mutations

An APP Mutation Family Exhibiting White Matter Hyperintensities and Cortical Calcification in East China

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

Mutation profile of APP, PSEN1, and PSEN2 in Chinese familial Alzheimer's disease

Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Mutation Screening in Chinese Patients with Familial Alzheimer's Disease by Whole-Exome Sequencing.

Clinical and genetic characteristics in a central-southern Chinese cohort of early-onset Alzheimer's disease

Genetic Influences on White Matter and Metabolism Abnormal Change in Alzheimer's Disease: Meta-analysis for Neuroimaging Research on Presenilin 1 Mutation

Clinical and Genetic Analysis of Early-Onset Alzheimer's Disease in Two Chinese Han Families with Presenilin-1 Mutations

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

APP, PSEN1, and PSEN2 Mutations in Asian Patients with Early-Onset Alzheimer Disease

Mutation Screening and Association Study of the Neprilysin Gene in Sporadic Alzheimer's Disease in Chinese Persons.

APP, PSEN1, and PSEN2 Variants in Alzheimer’s Disease: Systematic Re-evaluation According to ACMG Guidelines

The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family

Amyloid-β1–43 cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations

Probable Novel APP Met671Leu Mutation in a Chinese Han Family with Early-Onset Alzheimer's Disease

Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease

P3-395: Mean Age-of-onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased Aβ42 and Decreased Aβ40

Genetic Analysis of PICK1 Gene in Alzheimer's Disease: A Study for Finding a New Gene Target